Category: MS Research Study and Reports

Featured image for “Smoldering‐Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions –”

Smoldering‐Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions –

Abstract Despite therapeutic suppression of relapses, multiple sclerosis (MS) patients often experience subtle deterioration, which extends beyond the definition of…

Stuart Schlossman

Featured image for “Understanding PIRA in Multiple Sclerosis”

Understanding PIRA in Multiple Sclerosis

Detailed exploration of studies evaluating the use of highly effective treatments have unveiled the clinical concept of Progression Independent of…

Stuart Schlossman

Featured image for “Could CAR T cell therapy change the way we treat autoimmune diseases?”

Could CAR T cell therapy change the way we treat autoimmune diseases?

CAR T cell therapy is now being studied in autoimmune diseases, including: The immune system is the body’s natural defense…

Stuart Schlossman

Different lymphocyte counts of ms patients treated with ofatumumab and ocrelizumab

Christoph Friedli 1 2, Nik Krajnc 3 4, Helly N Hammer 1, Stefanie Marti 1, Tobias Zrzavy 3 4, Maria E Evangelopoulos 5, Ioanna Kapsali 5, Paulus Rommer 3 4, Thomas Berger 3 4, Andrew Chan 1, Gabriel Bsteh 3 4, Robert Hoepner 1 Affiliations expand Abstract Introduction: Patients with Multiple…

Stuart Schlossman

Featured image for “Multiple Sclerosis: Can a Blood Test Detect MS Years Before Symptoms Appear? New Research Encouraging”

Multiple Sclerosis: Can a Blood Test Detect MS Years Before Symptoms Appear? New Research Encouraging

Written By: John Fernandez Published: May 1, 2024 Disponible en Español New clinical trial findings could advance the early treatment for patients…

Stuart Schlossman

Featured image for “‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit’”

‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit’

In Phase 2 trials, drinkable medication with gold nanocrystals significantly reduced symptoms  By Melissa Rudy Fox News – Published April 30, 2024 5:30am…

Stuart Schlossman

Featured image for “A Smoldering Process: A New Way of Thinking about Multiple Sclerosis”

A Smoldering Process: A New Way of Thinking about Multiple Sclerosis

Published on: October 4, 2023 Our understanding of the biology of multiple sclerosis is changing. New research sheds light on…

Stuart Schlossman

Featured image for “PET scans reveal ‘smoldering’ inflammation in patients with MS”

PET scans reveal ‘smoldering’ inflammation in patients with MS

April 26, 2024 A new study suggests positron emission tomography brain scans could reveal hidden inflammation in patients with multiple…

Stuart Schlossman

Featured image for “Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (sanofi.com)”

Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis (sanofi.com)

April 17, 2024 Download PDF New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis…

Stuart Schlossman

Featured image for “Apr 17, 2024 – Press Release: Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis”

Apr 17, 2024 – Press Release: Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment-naïve people with relapsing multiple sclerosis

Apr 17, 2024 EAST HANOVER, N.J., April 17, 2024 — Novartis today announced data from the ALITHIOS open-label extension study showing sustained…

Stuart Schlossman

Categories

Latest Blog Posts